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Does C6-Ceramide induce activation of a rectifying chloride channel 
(ORCC) in vivo in patients with CysSc Fibrosis 
C. Rokahr 1, F. Mekus 1, U. Laabs 1, B. Tf immler 1,F. Lang 2, M. B al lmann 1 
iMedicaI School Hamu~ver MHH-Kinderklinik, Hannover wu] 2University of 
l~binge~ Universi~t l~binge~ Physiologisches Institut, T~binge~ Germany 
The hal lmark of CF is a defective activation of chloride channels caused by 
mutations in the CFTR gene. A l ternat ive pathways of chlor ide transport, 
independent of CFFR, represent a therapeutic concept for CF. It was shown that 
CD95 receptor tr iggering activates in peripheral blood lymphc~ytes from both 
healthy individuals and CF patients ORCC, an effect mediated by C6 cer amide and 
src l ike tyrosine kinase p561ck. In this study we investigated the ha vivo effect of 
ceramide on human respiratory epithel ium using nasal potential difference 
meas'arement ( PD). 
Mettu~ds: NPD was determined by measuring the potential difference in values 
between an exploring catheter positioned under the inferior nasal turbinate and a 
reference bridge fomed by a subcutaneous neddle ha the forearm, which is 
iscelectric with the submucosal space of the nasal epithelium. 8 healthy and 9 CF 
patients were measured each ha both nostrils using a standardised superfusion 
protc~ol. Superfusion ( lml /min)  started with PBS, fol lowed by amilor ide 
(10 ~ mmol) and CI free solution containing amiloride. C6 Cer amide was dissolved 
ha 98% ethanol and added to the CI free solution(final ceramide concentration I(X) 
~tmol). The epithel ium was perfused for 30 min. ha the last step ceramide was 
replaced by isoprenaline. To determine the ceramide eff ct, ethanol without 
ceramide was added to the CI free solution in 5 controls. 
Results: Super fusion of the nasal epithel ium with cer amide showed a depolarisation 
effect ha CF (mean + SD) 4.7 mV + 7 mV vs 1.2 mV + 9.3 mV in controls. Ethanol 
without ceramide showed a hyperpolarisation ha controls (mean + SD) 3.1 mV + 7.1 
mV. 
Discussion: Supeffusion of the nasal epithel ium with cer amide could not restore the 
electrophysiological abnormalities caused by the CFTR defect CFTR independent 
activation of ORCC by ceramide is shown in cell attached patch clamp experiments 
ha lymphccytes, but not in respirator3, epithel ia in vivo. 
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Pulmonary Function and Pseudomonas aeruginosa colonization in 
Pediatric CF patients after aggressive treatment of Pseudomonas 
aeruginosa "First Growth" 
G Davidson, Y. Lil lquist, A. Gr avelle, S. Jenkins, M. Mcl lwaine 
Cystic Fibro~is Clinic, BCChiMren's Hospital, l&ncouver; British Columbia, CwuMa 
Pseudomonas aeruginosa (Pa) is a common respiratory pathogen ha individuals with 
Oy stic Fibrosis (CF), eventually colonizing most CF patients. The presence of Pa in 
CF is associated with significantly greater decline in pulmonary function and 
increased need for hospitalization. For the past decade, we  have followed an 
aggressive treatment protc~ol for "First Growth" of Pa ha respiratory cultures from 
patients attending our paediatric (ages 0 18yr) CF clinic, using 2 weeks iv 
Piper acil l in + Tobr amycin, fol lowed by 3 weeks of oral Cipr oflaxacin + 3 6 months 
of nebulized colistin. We have reviewed the r sults of this approach ha our clinic 
patients (n 124 140). Mean age of Pa "First Growth" was 7.8 years (range 6 mos 
to 16 yr). Success rate for Pa clearance was 85%. As a result of this intervention, the 
percentage of Pa colonized CF chi ldren attending our clinic has decreased from 
44% ha 1995 to 14% in 2CO4. We have reviewed the effect of this treatment prot c~ol 
on pulmonary function. The overall mean FEV1 for all chi ldren attending our CF 
clinic, aged 6 17 (n 90) is 89.6% predicted, mad manual decl ine in FEV1 1.45% 
per year. For those chronically colonized with Pa (n 18), annual decl ine in FEV1 
was 3.09% compared to 0.76% for the Pa negative group. In the Pa negative 
group, those who had never grown Pa had a mean FEV1 of 93.7% and an annual 
change of +0.1%, whereas the group who were cleared of Pa fol lowing treatment, 
the mean FEV1 was 95.5% predicted mad annual change 1.34%. We conclude that 
close surveil lance and aggressive treatment of Pa in CF patients can decrease the 
prevalence of chronic colonization and favourably affect pulmonary function. 
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Towards zero prevalence of chronic Pseudomonas aeruginosa 
infection in pediatric paSents 
P. Lebecque, J. Gigi, K. Zylberberg, G. Reychler, T. Leal 
Cliniques St LuG University of Louvab; Brussels, Belgium 
Data from the Belgian Cystic Fibrosis Registry consistently show that in one of the 
7 Belgian cystic fibrosis reference centres, the prevalence of Pseuclomonas 
aeruginosa (Ps a) (last re piratory culture of the year) has stood at around 25% for 
several years, roughly halt" that observed at the national level. They also suggest that 
a specific antibiotic treatment s rategy might have contributed to this particularity. 
We aim to report the characteristics of non transplanted CF patients in our clinic, 
particularly as regards their bacteriological status. Cbronic infection by Ps a is 
defined according to Lee et al. (J Oyst Fibros 2C~)3;2:29 34). 
At the end of 2C~)3, the prevalence of Ps a is 20.7% (n 116). The cbronic 
colonization rate is 19.8 % but only 2.8% ha patients aged under 18 (n~2) .  
Serologic data are ha agreement with these findings. Most pediatric patients (95%) 
are prescribed hahaled antibiotic therapy, at least on an intermittent basis, even 
tough Ps a had never been isolated from the respiratory tract ha the majority of them 
(54%). The spirometric parameters of patients aged between 6 and under 18 are 
particularly encouraging (average FEV1 : 94% pr., FEV1 > 90% pr.: 70%, FEV1 
< 40% pr.: 0%). 
We have reported a distinctly low rate of chronic colonization by Ps a ha pediatric 
CF patients and bel ieve that a strategy of early, often * prophylactic ~ use of low 
dose inhaled antibiotics, progressively implemented for over 15 years has greatly 
contributed to these results. This policy is to some extent similar to the experience 
reported by Heinzl  et al. (Pediatr Pulmonol. 2C~)2;33:32 7). Given the major impact 
of cbronic Ps a colonization on prognosis ha CF, it is suggested that  large 
prospective study of this approach is warranted. 
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Seasonal variation in the number or the severity of pulmonary 
exacerbations in adult CF patients 
W.D. Smith, J.K.A Wilmot, N.A. Jarad 
Adult CF Centre, Bristol Royal Infirmaop, Bristol, BS2 8HW 
Aim of study: The aim of this research is to determine any seasonal variation ha the 
frequency and severity of pulmonary exacerbations ha adult CF patients in our 
centre. 
Patients and methods: This is a retrospective study. Exacerbations over 5 years from 
January 1999 to December 2CO3 were recorded. Exacerbations were considered to 
be severe when intravenous antibiotics were needed and mild when oral antibiotics 
were given. Data on age, sex, FEV1 and performance score were obtained. Routine 
or per operative antibiotics were excluded from the analyses. The year was divided 
into 'hot seasons' from Apri l  to September and 'cold season' from October to 
March. Patients were divided into two groups according to their general  
performance score; group 1 had good performance score and group 2 had worse 
performance status. 
Results: Data on 72 patients were investigated. Data on 59 patients were deemed to 
be sufficient for analysis. Patients in group 2 experienced greater number of both 
mild and severe exacerbations than group 1 (P<0.01 for each). There was no 
statistical difference of the number of exacerbations during cold seasons compared 
to those during hot seasons for either group. Age, sex and FEV1 did not affect the 
seasonal variation ha exacerbations. 
Conclusion: The present study demonstrates that there is no seasonal variation ha 
the frequency or the severity of pulmonary exacerbations ha CF patients irrespective 
of markers of disease severity. The manpower and bed resources in our centre need 
to be equally available tbroughout the year. 
